Updated Data Confirm Benefit of Single SBRT Dose for NSCLC
This video examines updated data from a phase II trial that compared a single dose of high-intensity SBRT with a standard three-dose schedule as treatment for patients with non-small-cell lung cancer.
In this video, Anurag Singh, MD, of the Roswell Park Cancer Institute, discusses updated data from a randomized phase II trial that compared a single dose of high-intensity stereotactic body radiation therapy (SBRT) with a standard three-dose schedule as treatment for patients with non-small-cell lung cancer (NSCLC).
The study, which included 98 patients, reported a 2-year overall survival rate of 72% for patients treated with the single 30-Gy fraction compared with 59% for those who received 60 Gy over three fractions. The frequency of grade 3 or higher adverse events was similar between the two groups (29% in patients who received one dose vs 35%).
Singh presented the results (abstract 4) at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.
Video courtesy of Roswell Park Cancer Institute.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
